Drug intelligence / Profile preview

ABT-182

Development stage: Preclinical
Lead developer: Abilita Therapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABT-182 is a preclinical-stage therapeutic candidate being developed by Abilita Therapeutics for the treatment of solid tumors. It is an Fc-fused single-domain antibody (Fc-VHH) that targets C-C chemokine receptor type 8 (CCR8). CCR8 is predominantly expressed on tumor-infiltrating regulatory T cells (Tregs), which play a key role in immunosuppression within the tumor microenvironment. By targeting CCR8, ABT-182 is designed to selectively deplete these immunosuppressive Tregs, thereby enhancing the anti-tumor immune response.

Targets

CCR8

Beyond the preview

Go deeper on ABT-182.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABT-182.

Explore the full profile